BioSpace News Archive

Tiziana Life Sciences plc announces an interview with the Chairman of its’ Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.

Madrigal Pharmaceuticals, Inc. announced achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH.

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the election of Laura A. Williams, M.D., MPH to its Board of Directors.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, announced positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces that Hannah Valantine, MD has joined CareDx’s Board of Directors.

XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Dr. Stephen Haworth will join the XORTX management team in the role of Chief Medical Officer.

Oncolytics Biotech® Inc. announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021.

Alkermes plc (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research related to healthcare resource use (HRU) among veterans with alcohol dependence.

Giiant Pharma inc. announced that is closed an additional financing of $750,000 from AQC Capital and $500,000 from CQDM for a total of $1.25 million.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of hypertension.